Novo/Catalent: Deal to Increase Weight-Loss Blockbuster Wegovy’s Supply May Raise Questions in Europe About Manufacturing Restrictions

Published on May 15, 2024

Novo Holdings’ proposed $16.5 billion acquisition of Catalent (CTLT) is likely to trigger European Commission questions over rival drugmakers’ access to critical manufacturing facilities and may require at the very least supply guarantees to quell concerns, according to a Capitol Forum analysis.

Already have an account? Log in.

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.

View Only Unlocked Articles

Copyright ©2024 The Capitol Forum. All Rights Reserved.